Dj. Mcrobie et al., THE EFFECTS OF DIABETES ON PLACENTAL AROMATASE-ACTIVITY, Journal of steroid biochemistry and molecular biology, 63(1-3), 1997, pp. 147-153
Diabetes complicates 2-3% of all pregnancies and is associated with an
increase in both perinatal morbidity and mortality, though reasons fo
r these adverse outcomes are unknown. Estrogen biosynthesis is a criti
cal factor during pregnancy and is carried out in the placenta via aro
matase (cytochrome P450 19A1), which catalyzes the conversion of C-19
androgens to C-18 estrogens. Previous studies have shown that hormones
such as insulin-like growth factors and insulin regulate aromatase ac
tivity when studied in vitro. Interestingly, levels of these hormones
are altered in patients with diabetes. Thus, we hypothesized that the
presence of maternal diabetes may alter placental aromatase activity a
nd thus estrogen biosynthesis, possibly serving as one factor in the a
dverse outcomes of babies born to mothers with diabetes. To this end,
we measured the production of 19-hydroxyandrostenedione, 19-oxoadroste
nedione and estrone in 30 placental tissues from diabetic patients, us
ing [7-H-3]androst-4-ene-3,17-dione as a model substrate for aromatase
(P450 19A1). A statistical difference was detected in the percentage
of 19-oxoandrostenedione formed between the overt and control groups (
P < 0.05). Additionally, NADPH P450-reductase levels were measured in
these same tissues to determine whether alterations in this enzyme nec
essary for aromatase activity could be affected by diabetes. No differ
ences in reductase levels were detected among the patient groups. Howe
ver, a statistical correlation was found between NADPH P450-reductase
activity and the formation velocities of all three estrogen products (
P < 0.05), Thus, it appears that the presence of diabetes does not aff
ect placental aromatase activity. (C) 1997 Elsevier Science Ltd. All r
ights reserved.